Volume 87 Issue 30 | p. 46 | Concentrates
Issue Date: July 27, 2009

Better Biosynthesis Building Blocks

Bacterium genome analysis turns up a novel pathway to salinosporamide anticancer agents that may have general biosynthesis applications
Department: Science & Technology
News Channels: JACS In C&EN
Keywords: salinosporamide, natural products, biosynthesis, genomics

A pair of biosynthetic studies may provide information that makes it easier to access analogs of the salinosporamides, a promising class of anticancer agents. Bradley S. Moore of Scripps Institution of Oceanography and the University of California, San Diego, teamed with Kevin A. Reynolds of Portland State University and colleagues to analyze the genome of Salinispora tropica, a deep-sea-dwelling bacterium that makes salinosporamides. They found that salinosporamides are biosynthesized by an unusual polyketide synthase (PKS) enzyme (Proc. Natl. Acad. Sci. USA, DOI: 10.1073/pnas.0901237106). The team then explored the enzyme's substrate specificity and learned that it can incorporate a broad range of substrates, including brominated and fluorinated compounds, into the salinosporamide skeleton (J. Am. Chem. Soc., DOI: 10.1021/ja9042824). PKS enzymes naturally make erythromycin, rapamycin, and a host of other drugs. They tend to accept a limited set of substrates, however, leaving few opportunities for further elaboration. In contrast, the salinosporamide-making PKS accepts substrates with functionalizable moieties, which might aid efforts to generate novel drug derivatives via fermentation, says Yi Tang, who studies biosynthesis at UCLA.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment